Navigation Links
Angiotech Pharmaceuticals, Inc. announces conference call and webcast
Date:7/6/2009

Second Quarter 2009 Financial Results

VANCOUVER, July 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the second quarter ended June 30, 2009, on Thursday August 6, 2009 at 11:00 AM ET (8:00 AM Pacific).

    Dial-in information for the earnings call on August 6, 2009 is as
    follows:
    North America (toll-free): 866.700.6067
    International: 617.213.8834
    Enter Passcode: 91816046

A live webcast of the earnings call will be available to interested parties through Angiotech's website at www.angiotech.com in the Investor Relations section.

A press release announcing Angiotech's financial results will be issued prior to the call on August 6th at approximately 8:00 AM ET (5:00 AM Pacific).

An archived replay of the call will be available until August 13, 2009.

    Replay information is as follows:
    North America (toll-free): 888.286.8010
    International: 617.801.6888
    Enter Passcode: 23483326

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market ... Administration (FDA) for the use of Medtronic,s SynchroMed ... a newly developed catheter) for use with United ... to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... First 9 Months Compared with Fiscal 2007,Net Income To ... MOUNTAIN VIEW, Calif., Jan. 24 Pharsight,Corporation (Nasdaq: ... strategic,services designed to optimize clinical drug development, today announced,financial ... December 31,2007. Revenue for the third quarter was $7.4 ...
... Call and Webcast Scheduled for Tuesday, February 5, ... NBIX ) announced today that the Company will report ... Nasdaq market closes,on Tuesday, February 5, 2008. Neurocrine will ... its financial results and provide a Company,update Tuesday afternoon, ...
... /PRNewswire-FirstCall/,-- Cephalon, Inc., (Nasdaq: CEPH ) announced ... Human Use (CHMP) of the European,Medicines Agency has ... buccal tablet pain medication. In March 2007, Cephalon,submitted ... treatment of,breakthrough pain in adult cancer patients who ...
Cached Biology Technology:Pharsight Achieves $7.4 Million in Quarterly Revenue 2Pharsight Achieves $7.4 Million in Quarterly Revenue 3Pharsight Achieves $7.4 Million in Quarterly Revenue 4Pharsight Achieves $7.4 Million in Quarterly Revenue 5Pharsight Achieves $7.4 Million in Quarterly Revenue 6Pharsight Achieves $7.4 Million in Quarterly Revenue 7Pharsight Achieves $7.4 Million in Quarterly Revenue 8Pharsight Achieves $7.4 Million in Quarterly Revenue 9Pharsight Achieves $7.4 Million in Quarterly Revenue 10Pharsight Achieves $7.4 Million in Quarterly Revenue 11Pharsight Achieves $7.4 Million in Quarterly Revenue 12Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 3Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 4
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... A breakthrough in human stem cell research, producing embryonic-like ... the development of treatments for life-threatening illnesses, injuries and ... experts from the University of Texas Medical Branch and ... researchers and physicians with an ethical and reliable source ...
... rise, and the loss of sand dune plant habitats" ... to better understand the impacts of development and coastal ... the ever-shrinking strip of habitat between land and the ... simulated varying levels of sea-level rise to understand the ...
... the body, a virus such as HIV invades body cells ... Once inside the cell, the invading microbe's genetic material takes ... more copies of the virus, which then spill out to ... that once a virus begins fusing with a cell's membrane, ...
Cached Biology News:Insight into the processes of 'positive' and 'negative' learners 2Squeezing out dune plants 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3
B-FABP (FL-132)...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
... Lambda Protein Phosphatase ( ... protein phosphatase with activity ... and tyrosine residues. It ... product of the ORF221 ...
Strip Removal Tool 25/Box...
Biology Products: